Regulatory & Legal

Chinese data center giant VNET promotes Peter Zhang to SVP, signaling a focus on stability and governance as it navigates rapid AI-driven growth.

Irish firm InVera Medical wins CE Mark for a new varicose vein device, promising a less invasive, office-based treatment for a widespread condition.

Amplify ETFs plans to launch the YYYM fund, a 'fund of funds' offering systematic exposure to a portfolio of high-yield, tax-efficient municipal CEFs.

In a major strategic pivot, Elkem will trade its Silicones division to Bluestar in exchange for its majority stake, reshaping the firm into a focused metals company.

A Canadian safety equipment distributor, forged in the pandemic's chaos, may spin off its internal software, sparking a conversation about national tech resilience.

Hong Kong's Powell Max resolved a critical Nasdaq compliance issue, but a look at its finances and a second regulatory notice reveals greater challenges.

Vibrant festivals in Cairo and Rabat celebrate the Chinese New Year, revealing a strategic cultural diplomacy effort to deepen ties in the Middle East.

The 2026 International Talents Conference highlights Hong Kong's aggressive strategy to attract global professionals and integrate with the Greater Bay Area.

A firm promising huge returns and easy market access is gaining attention, but a lack of transparency and a controversial business model raise serious questions.

With a top Hong Kong director and stars on the NBA stage and Disney+, Catwalk Entertainment is building a content empire to take Mandarin media global.

Canada's largest P&C insurer swaps old debt for new capital, a strategic move to cut costs, enhance flexibility, and fuel its global expansion strategy.

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

A federal agency's safety warning has sparked a high-stakes legal fight, pitting a small business against regulators in a battle over science and survival.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

With revolutionary tech and a volatile stock, PureCycle's year-end update is a critical test of its operational progress and financial promises.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.